LipoScience Stock Price, News & Analysis (NASDAQ:LPDX)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About LipoScience (NASDAQ:LPDX)

LipoScience logoLipoScience, Inc. is a vitro diagnostic company. The Company's diagnostic test, the nuclear magnetic resonance (NMR) LipoProfile test, directly measures the number of low density lipoprotein (LDL), particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. The Company's Vantera system is the Company's automated clinical analyzer. As of January 25, 2013, over eight million NMR LipoProfile tests were ordered. The Vantera system is its automated clinical analyzer. In August 2012, the Company received Food and Drug Administration (FDA) clearance to market the Vantera system commercially to laboratories.

Receive LPDX News and Ratings via Email

Sign-up to receive the latest news and ratings for LPDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic & Testing Substances Manufacturers
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:LPDX
CUSIP53630M10
WebN/A
Phone+1-919-2121999

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

LipoScience (NASDAQ:LPDX) Frequently Asked Questions

What is LipoScience's stock symbol?

LipoScience trades on the NASDAQ under the ticker symbol "LPDX."

How were LipoScience's earnings last quarter?

LipoScience Inc (NASDAQ:LPDX) issued its quarterly earnings data on Wednesday, November, 12th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02. The biotechnology company earned $8.56 million during the quarter, compared to analysts' expectations of $8.80 million. During the same period in the prior year, the business earned ($0.31) EPS. View LipoScience's Earnings History.

Who are some of LipoScience's key competitors?

How do I buy LipoScience stock?

Shares of LipoScience can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact LipoScience?

LipoScience's mailing address is 2500 Sumner Blvd, RALEIGH, NC 27616-3235, United States. The biotechnology company can be reached via phone at +1-919-2121999.


MarketBeat Community Rating for LipoScience (LPDX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  88
MarketBeat's community ratings are surveys of what our community members think about LipoScience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

LipoScience (NASDAQ:LPDX) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

LipoScience (NASDAQ:LPDX) Earnings History and Estimates Chart

Earnings by Quarter for LipoScience (NASDAQ:LPDX)

LipoScience (NASDAQ LPDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/12/2014Q3 14($0.26)($0.28)$8.80 million$8.56 millionViewN/AView Earnings Details
8/12/2014Q2 2014($0.24)($0.27)$8.90 million$9.05 millionViewN/AView Earnings Details
5/12/2014Q1 14($0.19)($0.13)$12.25 million$12.01 millionViewN/AView Earnings Details
3/10/2014Q413($0.24)($0.17)$12.71 million$12.72 millionViewN/AView Earnings Details
11/5/2013Q3 2013($0.20)($0.31)ViewN/AView Earnings Details
8/6/2013Q2 2013($0.17)($0.17)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.16)($0.19)ViewN/AView Earnings Details
3/27/2013Q4 2012$0.02ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

LipoScience (NASDAQ:LPDX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for LipoScience (NASDAQ:LPDX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

LipoScience (NASDAQ LPDX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for LipoScience (NASDAQ:LPDX)

LipoScience (NASDAQ LPDX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/4/2013Daniel LevangieDirectorBuy10,000$4.17$41,700.001,122View SEC Filing  
12/4/2013E. Duffy McdonaldVPSell12,731$4.07$51,815.173,765View SEC Filing  
11/25/2013James HurleyDirectorBuy5,100$3.91$19,941.003,715View SEC Filing  
11/18/2013Robert Greczyn, Jr.CEOBuy10,000$4.15$41,500.009,091View SEC Filing  
1/30/2013Buzz BensonDirectorBuy50,000$9.00$450,000.00View SEC Filing  
1/30/2013Three Arch Capital LpMajor ShareholderBuy215,000$9.00$1,935,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

LipoScience (NASDAQ LPDX) News Headlines

Source:
No headlines for this company have been tracked by MarketBeat.com

SEC Filings

LipoScience (NASDAQ:LPDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

LipoScience (NASDAQ:LPDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

LipoScience (NASDAQ LPDX) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.